Published in Volume
90, Issue 5 (November 1992)
J Clin Invest. 1992;90(5):1666–1671.
doi:10.1172/JCI116038.
Copyright ©
1992, The American Society for
Clinical Investigation.
Research Article
Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations.
H Watkins, L Thierfelder, D S Hwang, W McKenna, J G Seidman and C E Seidman
Cardiology Division, Brigham and Women's Hospital, Boston, Massachusetts.
Published November 1992
Hypertrophic cardiomyopathy occurs as an autosomal dominant familial disorder or as a sporadic disease without familial involvement. While missense mutations in the beta cardiac myosin heavy chain (MHC) gene account for approximately half of all cases of familial hypertrophic cardiomyopathy, the molecular causes of sporadic hypertrophic cardiomyopathy are unknown. To determine whether beta cardiac MHC mutations are also associated with sporadic disease, we screened this gene in seven individuals with sporadic hypertrophic cardiomyopathy. Mutations in the beta cardiac MHC genes were identified in two probands with sporadic disease. In that their parents were neither clinically nor genetically affected, we conclude that mutations in each proband arose de novo. Transmission of the mutation and disease to an offspring occurred in one pedigree, predicting that these are germline mutations. The demonstration of hypertrophic cardiomyopathy arising within a pedigree coincident with the appearance of a de novo mutation provides compelling genetic evidence that beta cardiac MHC mutations cause this disease. We suggest that de novo mutations account for some instances of sporadic hypertrophic cardiomyopathy and that these mutations can be transmitted to children. The clinical benefits of defining mutations responsible for familial hypertrophic cardiomyopathy should also be available to some patients with sporadic disease.
Browse pages
Click on an image below to see the page. View
PDF of the complete article